Deucravacitinib in patients with plaque psoriasis who did not have adequate response to apremilast is effective and ...
Deucravacitinib was effective and worked faster than placebo through 52 weeks in patients with moderate-to-severe plaque psoriasis. The phase 3 trial, which appears in the Journal of Dermatological ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 ...
Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial The overall safety profile of deucravacitinib in this study ...
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, ...
The approval was based on data from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials in adults with moderate to severe plaque psoriasis. The Food and Drug Administration (FDA) has approved Sotyktu ™ ...
Please provide your email address to receive an email when new articles are posted on . In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results